L1 cell adhesion molecule (L1CAM) overexpression is often associated with bad prognosis in various human carcinomas. Recent studies also suggest a role of L1CAM in pancreatic ductal adenocarcinomas (PDAC). To further address its contribution, we expressed functional domains of L1CAM in PT45-P1 PDAC cells. We found that L1CAM that is full length (L1-FL), but neither the soluble ectodomain (L1ecto) nor the cytoplasmic part (L1cyt), could enhance cell proliferation or tumour growth in mice. Expression of L1-FL resulted in constitutive activation of NF-jB, which was abolished by L1CAM knockdown. We showed that the expression of IL-1b was selectively upregulated by L1-FL, and increased IL-1b levels were instrumental for sustained NF-jB activation. IL-1b production and NF-jB activation were abolished by knockdown of a5-integrin and integrin-linked kinase, but insensitive to depletion of L1CAM cleavage proteinases. Supporting these data, PT45-P1 cells transduced with an L1CAM mutant deficient in integrin binding (L1-RGE) did not support the described L1-FL functions. Our results suggest that membranous L1CAM interacts with RGD-binding integrins, leading to sustained NF-jB activation by IL-1b production and autocrine/paracrine signalling. The unravelling of this novel mechanism sheds new light on the important role of L1CAM expression in PDAC cells.
Introduction
Pancreatic cancer is a highly aggressive disease that is mostly detected in an advanced stage. Owing to its exocrine functions, it frequently develops multiple metastases and is the fourth leading cause of cancerrelated death in the United States. (Neoptolemos et al., 2004; Jemal et al., 2007) . Resection of the tumour is still the only option that offers a chance for cure hence, the prognosis for patients is poor and more than 80% die within 5 years after surgery. Pancreatic cancer is often refractory to conventional chemotherapeutic treatment because of the frequent development of profound chemoresistance. This chemoresistant phenotype is often mediated by the constitutive activation of the transcription factor NF-kB, resulting from the autocrine production of interleukin1b (IL-1b) (Arlt et al., 2002; Muerkoster et al., 2005) . An important goal is to understand the molecular parameters involved not only in chemoresistance but also in pancreatic carcinoma progression.
The L1 cell adhesion molecule (L1CAM) is a 200-220 kDa transmembrane glycoprotein of the immunoglobulin superfamily composed of six immunoglobulin-like domains and five fibronectin type III repeats, followed by a transmembrane region and a highly conserved cytoplasmic tail (Moos et al., 1988) . L1CAM can interact with itself (homophilic) and with heterophilic ligands such as integrins, CD24, neurocan, neuropilin-1 and other members of the neural cell adhesion family (Brummendorf et al., 1998; Hortsch, 2000) . Many binding sites in the L1CAM molecule have already been mapped. The RGD site(s) in the sixth immunoglobulin domain (one in human, two in mouse) support a5-and av-integrin-mediated cell binding (Ruppert et al., 1995; Montgomery et al., 1996; Oleszewski et al., 1999) . Homophilic L1CAM interaction has been recently mapped to immunoglobulin domains 1-4 (Gouveia et al., 2008) .
L1CAM was initially described in the nervous system, in which it is important for cell migration and axon outgrowth. Subsequent work has shown overexpression of L1CAM in a variety of human tumours, in which it is associated with bad prognosis and metastases formation (Thies et al., 2002; Fogel et al., 2003a, b; Boo et al., 2007; Kaifi et al., 2007) . Furthermore, L1CAM was detected in tumour-associated endothelium (Issa et al., 2009; Maddaluno et al., 2009) . Expression of L1CAM was also described in pancreatic ductal adenocarcinomas (PDACs) (Sebens Muerkoster et al., 2007 Geismann et al., 2009) . Accumulating evidence suggests an important role of L1CAM in the malignancy of this tumour (Sebens Muerkoster et al., 2007 Geismann et al., 2009) . The mechanism of L1CAM-mediated tumour progression is not clearly established. Previous studies showed that L1CAM augments tumour growth in NOD/Scid mice, enhances cell motility on extracellular matrix proteins and increases matrigel invasion (Mechtersheimer et al., 2001; Thelen et al., 2002; Silletti et al., 2004; Gast et al., 2005; Gavert et al., 2005; Meier et al., 2006) . Interference with L1CAM expression by genetic manipulation or by selective knockdown was found to be growth inhibitory (Primiano et al., 2003; Bao et al., 2008) . Studies from different laboratories showed L1CAM-dependent gene expression in mouse and human carcinoma cells (Silletti et al., 2004; Gavert et al., 2007; Gast et al., 2008a) that is relevant for understanding the mechanisms of L1CAM tumour-promoting effects.
To further analyse the mechanisms of L1CAM signalling, we expressed functional domains of L1CAM in PT45-P1 PDAC cells. We show that only L1CAM that is full-length (L1-FL), but neither the soluble L1CAM (L1ecto) nor the cytoplasmic part (L1cyt), can promote cell proliferation and tumour growth in vivo. Only L1-FL-expressing cells support NF-kB activation and upregulate various genes including the prototype NF-kB inducer IL-1b. The L1CAM-mediated upregulation of IL-1b expression seems to be instrumental for NF-kB activation and requires the RGD motive in L1CAM and integrin signalling. Our work identifies important novel downstream effects of L1CAM that help to understand the molecular mechanisms leading to tumour progression promoted by L1CAM.
Results

Characterization of PT45-P1 cells overexpressing L1CAM domains
We transduced PT45-P1 pancreatic adenocarcinoma cells with functional domains of L1-FL, cytoplasmic L1CAM (L1cyt) or L1CAM ectodomain (L1ecto), as outlined ( Figure 1a) . The selected cells stably expressed L1CAM fragments as detected by quantitative real-time (qRT)-PCR ( Figure 1b) and by fluorescence-activated cell sorting analysis using antibodies to the cytoplasmic (mAb 74 5H7) or the extracellular portion of L1CAM (mAb L1-11A and L1-9.3) (Figure 1c ). L1-FL and L1cyt were visualized by western blot analysis of cell lysates (Figure 1d ). L1-FL also showed detectable amounts of L1-32 (Figure 1d ), representing the membrane-retained cleavage fragment resulting from ADAM10-mediated ectodomain shedding of L1CAM (Gutwein et al., 2000; Mechtersheimer et al., 2001) . Further analysis showed that cleavage of L1-FL was augmented by Phorbol 12-myristate 13-acetate (PMA) treatment and was blocked by the metalloproteinase inhibitor BB-3644 (Supplementary Figures 1a and b) . Similar results were obtained with Panc-1 cells endogenously expressing L1CAM (Supplementary Figure 1b right panel) . As shown previously in ovarian carcinoma cells (Riedle et al., 2009) , treatment with presenilin inhibitor DAPT increased the amount of L1-32 by preventing it from being processed further in both PT45-P1-L1-FL and Panc-1 cells (Supplementary Figure 1b) . There was no effect of treatment observed in L1cyt-expressing cells (data not shown).
L1ecto was secreted in large amounts into the medium (Figure 1e ) and was detected by western blot (Figure 1d ) in cell lysates and L1CAM-specific capture enzymelinked immunosorbent assay (ELISA) (Figure 1e ). As expected, L1-FL cells released significantly less soluble L1CAM into the medium (Figure 1e ). The amount of soluble L1CAM from L1-FL in the supernatant was increased by PMA treatment, whereas there was no effect on the release of L1ecto (Supplementary Figure 1a) . These results implicate that L1CAM processing in pancreatic cells is similar to that of other carcinoma cells.
L1-FL shows nuclear translocation that is increased by PMA treatment
In a recent study, we have shown that the C-terminal L1CAM fragment translocates into the nucleus depending on proteolysis by ADAM10 and presenilin (Riedle et al., 2009) . We examined nuclear translocation in PT45-P1 cells expressing L1-FL and L1cyt by fluorescence microscopy, using pcytL1 to the cytoplasmic tail of L1CAM (Riedle et al., 2009) . Increased nuclear staining of L1CAM was observed following treatment of L1-FL cells with PMA ( Figure 1f ). PMA-induced nuclear translocation of L1-FL was clearly blocked by pretreatment with DAPT ( Figure 1f and Supplementary  Figure 2 ). In contrast, no effect of the inhibitor or PMA was observed in PT45-P1 cells expressing L1cyt, suggesting that L1cyt could reach the nucleus without proteolytic processing (Figure 1f and Supplementary  Figure 2 ). PT45-P1 expressing L1CAM full-length augments cell proliferation and tumour growth in vivo Next, we analysed the impact of L1CAM domains on cellular functions in PDAC cells. Therefore, we tested cell proliferation of PT45-P1 cells expressing various L1CAM constructs. A clear growth-promoting effect of L1-FL compared with mock-transfected cells was noted after 96 h (Figure 2a ). Despite the significantly higher amounts of released L1ecto, only a marginal effect was observed in L1ecto cells.
To test whether enhanced proliferation in vitro resulted in augmented tumour growth in vivo, we injected the different cell lines into NOD/Scid mice. Moreover, in vivo, only PT45-P1 cells expressing L1-FL showed significantly enhanced tumour growth compared with mock-transduced cells (Figures 2b and c) . In contrast, tumour growth of L1ecto and L1cyt cells was comparable to that of PT45-P1 mock-transduced cells (Figures 2b and c) .
PT45-P1 cells expressing L1-FL promote gene regulation
Previous research has shown that L1CAM expression supports gene regulation in tumour cells. To establish expression profiles for PT45-P1 L1CAM-expressing cells, we performed a DNA chip screen. Schematically, the expression differences between PT45-P1 mock and L1-FL are summarized in Figure 3a. A total of 226 genes were selectively regulated in L1-FLexpressing cells.
To analyse whether differential gene expression had an impact on cellular function of PDACs cells, we selected candidate genes that were described to be involved in tumour progression and were expressed in pancreatic tumours. We verified the results for the selected genes by qRT-PCR and included L1ecto and L1cyt cells into the analysis. We observed that the expression of IL-11, IL-1b, S100A4 and MDK was significantly upregulated by L1-FL, but not by L1ecto or L1cyt (Figure 3b ). To analyse whether the same genes were also upregulated under in vivo growth conditions, we isolated RNA from tumours grown in NOD/Scid mice. Using qRT-PCR analysis, we confirmed that IL-11 and IL-1b were upregulated in tumours derived from L1-FL-expressing PT45-P1 cells compared with mock, L1cyt-or L1ecto-expressing cells. The effects were even more apparent in the in vivo background (Figure 3c ). In contrast, the expression of MDK and S100A4 was also increased in PT45-P1 L1ecto-derived tumours (Figure 3c ). Cross-reactivity of qRT-PCR primers to mouse sequences was excluded (data not shown). As expected, levels of IL-1b protein, as measured by IL-1b-specific ELISA, were elevated in L1-FL compared with mock cells both in vitro (supernatant) and in vivo (tumour lysate) (Figure 3d ).
L1-FL induces constitutive NF-kB activation in PT45-P1 cells
We noted that many of the identified genes were related to the NF-kB signalling pathway. Most remarkable was Cells were stained directly with antibodies to the ectodomain of L1CAM (L1-11A) (extracellular (EC)) or after permeabilization and fixation with mAb to the intracellular domain (74 5H7) (intracellular (IC)), followed by staining with a PE-conjugated goat anti-mouse IgG. (d) Western blot analysis of tumour cell lysates using pcytL1 to the cytoplasmic portion of L1CAM (top) and mAb L1-9.3 to the ectodomain of L1CAM (bottom). *marks an unspecific band. (e) Soluble L1CAM in the tissue culture supernatant of dense cultures was analysed by L1CAM-specific capture ELISA. (f) Nuclear translocation of L1CAM. Cells were pretreated overnight with DMSO (vehicle control) or DAPT (10 mM) at 37 1C and than stimulated with PMA for 2 h. Cells were fixed, permeabilized with methanol (À20 1C) and stained with pcytL1 and Alexa488-conjugated anti-rabbit IgG. Note that methanol treatment reduces membranous L1CAM staining but leaves intact intracellular and nuclear staining. **Po0.01, ***Po0.001. 
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the role of IL-1b as a prototype inducer of NF-kB activation. Furthermore, the autocrine production of IL-1b was previously described to induce sustained NF-kB activation in PDAC cells (Arlt et al., 2002) . Therefore, we compared the NF-kB activity between PT45-P1 cells expressing various L1CAM domains, using an NF-kB-luciferase reporter plasmid. We observed significantly increased NF-kB activation in L1-FL versus mock-transduced cells (Figure 4a ). L1ecto showed an intermediate activation, whereas L1cyt-expressing cells were similar to mock-transduced cells (Figure 4a ). To confirm the enhanced NF-kB activation, we analysed phosphorylation levels of the NF-kB subunit p65 in PT45-P1-mock and L1-FL cells by western blot analysis of total cell extracts ( Figure 4b ). We observed increased phosphorylation of p65 in the lysate from L1CAM-expressing PT45-P1 cells (Figure 4b ).
To show that the intrinsic NF-kB activity was due to enhanced IL-1b expression, we used a neutralizing mAb to IL-1b and to IL-1 receptor that efficiently inhibits binding and signalling of IL-1b. Both compounds 
α hu βActin L1CAM knockdown reverts constitutive NF-kB activation To further show the role of L1CAM in constitutive NFkB activation, we used siRNA mediated knockdown. Depletion of L1CAM in PT45-P1-L1-FL cells led to a clear reduction of L1CAM as detected by qRT-PCR and western blotting (Figure 5a ), accompanied by a drop in IL-1b expression (Figure 5b ). L1CAM knockdown also reduced NF-kB activity as determined by luciferase reporter assay but had only a nonsignificant effect in mock cells (Figure 5c ).
We examined whether L1CAM was involved in NFkB activity in Panc-1 PDAC cells that endogenously express L1CAM. Indeed, the knockdown of L1CAM (Figure 5d ) almost completely suppressed the expression of IL-1b (Figure 5e ) and abolished the constitutive NFkB activation (Figure 5f ). Furthermore, depletion of L1CAM in Panc-1 resulted in a significant inhibition of proliferation (Figure 5g ). These data underline the fact that L1-FL has an important role in the constitutive NF-kB activation of pancreatic carcinoma cell lines.
Role of integrins in the constitutive NF-kB activation L1CAM is a ligand for several integrins such as a5b1, avb3, a IIb b3 and avb5. L1CAM on tumour cells can interact with integrins on neighbouring tumour cells or on stromal cells of the surrounding tissue. As suggested before, interaction between neighbouring tumour cells could lead to bidirectional signalling by L1CAM and integrins, as many cell types express both binding partners (Gast et al., 2008b) . To address the involvement of integrins in NF-kB activation, we examined the effect of integrin knockdown on IL-1b expression. The heavy chains of a5-and av-integrins were efficiently depleted as shown by qRT-PCR analysis (Figures 6a  and b) and fluorescence-activated cell sorting analysis with specific antibodies (data not shown). With respect 
to IL-1b expression, there was a threefold reduction observed after a5-integrin depletion (Figure 6a ), accompanied by a substantial loss of NF-kB activity (Figure 6a ). In contrast, knockdown of av-integrins had no significant effect on IL-1b message (Figure 6b) .
NF-kB has been described as a downstream target of integrin-mediated integrin-linked kinase (ILK) signalling (Legate et al., 2006) . To analyse whether ILK has a role in L1CAM-dependent NF-kB activation, ILK was knocked down by siRNA transfection. Indeed, depletion of ILK led to a reduction in IL-1b levels and concomitantly abolished sustained NF-kB activation in PT45-P1-L1-FL cells (Figure 6c ). It is noteworthy that, in Panc-1 cells, the knockdown of both a5-and av-integrin led to a decrease in IL-1b expression and a reduction in NF-kB activity (Figure 6e) , and ILK depletion in Panc-1 cells showed similar effects (data not shown). Together, these data support a central role for integrin signalling in L1CAM-mediated activation of the NF-kB pathway in pancreatic cancer cells. (e) a5-integrin or av-integrin was depleted in Panc-1 cells using specific siRNAs; the effect on IL-1b expression was determined by qRT-PCR and NF-kB actvity was measured by luciferase reporter assay. Data shown are representative of n ¼ 3 experiments. *Po0.05, **Po0.01, ***Po0.001.
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H Kiefel et al NF-kB activation by L1CAM is independent of L1CAM cleavage It is known that nuclear signalling of L1CAM involves proteolytic activity of ADAM10 and presenilins (Riedle et al., 2009) . We silenced ADAM10 to address the influence of L1CAM cleavage on IL-1b expression. The depletion of ADAM10 affected neither IL-1b expression (Figure 6d ) nor NF-kB activity (Figure 6d ). L1CAM can also be cleaved by ADAM17 (Maretzky et al., 2005; Stoeck et al., 2006a) . To formally rule out a possible function of ADAM17, we depleted ADAM17 by specific siRNA. Although ADAM17 was efficiently depleted in PT45-P1 cells, there was no effect on IL-1b expression (Supplementary Figure 3) . Similar results were obtained when presenilin-1 or presenilin-2 was depleted from cells by specific knockdown (Supplementary Figure 3 ) or when the cells were treated with TAPI-0 or DAPT to pharmacologically inhibit ADAM and presenilin activity (Supplementary Figure 3) . Collectively, these results suggest that the effect of L1CAM on IL-1b expression and NF-kB activity is independent of proteolytic processing by ADAM10/17 and presenilins. Instead, it requires integrins and integrin signalling.
The RGD motif in L1CAM is required for IL-1b production and NF-kB activation To further investigate the role of integrin binding in L1CAM-mediated NF-kB activation, we first analysed whether mAbs to distinct domains of L1CAM could block IL-1b expression. MAbs that bind to the first Ig domain (L1-9.3), the sixth Ig domain (L1-35.9) or the FNIII repeats (L1-11A) of L1CAM were selected. (Wolterink et al., 2010) . A significant effect on IL-1b production was only observed with mAb L1-39.5 to the sixth Ig domain (Figure 7a ). This domain contains RGD site(s) (one in human and two in mice) that are known to support a5-and av-integrin-mediated cell binding (Ruppert et al., 1995; Montgomery et al., 1996; Oleszewski et al., 1999) . To further investigate the role of the RGD motif, we expressed an L1-RGE mutant in PT45-P1 cells (see Figure 1a) . The expression levels, as determined by western blot or fluorescence-activated cell sorting analysis, were comparable between L1-FL and the L1-RGE mutant (Figures 7b and c) . To show that the L1-RGE mutant was indeed impaired in integrin binding, we isolated mutant and wild-type L1CAM protein from cellular lysate and carried out cell binding assays on immobilized protein. As expected, wild-type L1CAM supported cell binding that was integrin dependent as it was blocked in the presence of an RGDS peptide (Supplementary Figure 4) . In contrast, the L1-RGE mutant was unable to support cell binding by integrins (Supplementary Figure 4) .
To show that RGE mutagenesis had not altered other L1CAM-binding functions, we examined the homophilic binding to immobilized L1-Fc. Although PT45-P1 mock cells showed weak adhesion, the number of bound L1-FL-and L1-RGE-expressing cells was significantly increased (Supplementary Figure 4) , suggesting that homophilic binding of L1CAM is not impaired in the L1-RGE mutant.
Finally, we analysed IL-1b expression and NF-kB activity in PT45-P1-L1-RGE cells and observed that both were severely impaired (Figures 7d and e) . These results suggest that the L1-RGD motive has to interact with RGD-binding integrin to provoke the observed biological effects.
Discussion
In this paper, we generated PT45-P1 cell lines expressing various functional domains of L1CAM, namely, L1-FL, L1ecto and L1cyt. As expected, L1ecto cells released large amounts of soluble L1CAM into the medium. We observed a clear difference between the effects of L1-FLversus L1ecto-expressing cells. Only L1-FL cells supported enhanced cell proliferation and tumour growth in vivo and were clearly distinct in the pattern of 
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regulated genes in vitro. Although L1-FL upregulated the expression of IL-11, MDK, S100A4 and IL-1b, this was not seen in cells expressing L1ecto. In ex vivoderived tumours, there was an upregulation of MDK and S100A4 by L1ecto observed for reasons presently unknown. L1-FL-and L1ecto-expressing cells also differed in the level of NF-kB activation. Although L1-FL cells were consistently high in NF-kB activity as compared with mock or L1cyt cells, the effects of L1ecto were more diverse. IL-1b was described as a potent inducer of NF-kB activity in PDAC cells (Arlt et al., 2002) . Therefore, it was important to establish a link between elevated levels of IL-1b in L1-FL cells and the state of NF-kB activation in these cells. Using neutralizing antibodies to IL-1b and IL-1 receptor, we could provide compelling evidence that IL-1b indeed functioned in an autocrine manner to induce NF-kB activation. We also showed that specific inhibition of NF-kB could revert the augmented proliferation of L1-FL cells in vitro. Thus, the failure of PT45-P1 cells expressing L1ecto, L1cyt or mock cells to induce massive tumour growth in vivo could be due to the lack of IL-1b production and subsequent NF-kB activation. We conclude that the L1CAM-mediated induction of NF-kB activity is an important downstream event responsible for cell proliferation in vitro and tumour formation in vivo and most likely has a role in other cellular features, such as enhanced cell motility and invasion. Indeed, all these features are promoted by L1CAM expression in tumours. It should be noted that L1CAM expression and NF-kB activation are abundant in pancreatic cancer (Muerkoster et al., 2005) . However, it remains to be investigated whether a correlation between L1CAM expression and NF-kB activation is observed in human pancreatic adenocarcinoma in vivo.
How can L1-FL lead to the activation of IL-1b expression? We recently showed that L1CAM cleavage by ADAM10 and presenilins is required for nuclear translocation of L1CAM and L1CAM-dependent gene regulation (Riedle et al., 2009) . We first investigated whether cleavage and nuclear translocation were intact in PT45-P1 cells. As expected, L1CAM was cleaved by ADAMs and presenilins and was translocated into the nucleus. The translocation was enhanced when L1CAM cleavage was induced by PMA treatment of cells. In contrast to our expectation, we could not show a role for L1CAM cleavage in the induction of IL-1b expression. The knockdown of ADAM10, ADAM17, presinilin-1 and presinilin-2, as well as the pharmacological inhibition of shedding proteinases and presenilins by TAPI-0 and DAPT, respectively, did not affect the level of IL1b. In contrast, the depletion of a5-integrin (but not avintegrin) had a profound effect on IL-1b expression in PT45-P1-L1-FL cells that was similar to the knockdown of L1CAM. In Panc-1, the knockdown of a5-integrin and av-integrin led to a reduction in IL-1b expression and NF-kB activity, suggesting the role of both integrins in NF-kB activity in these cells. However, little is known about the exact mechanisms by which L1CAM and integrin ligation are integrated into IL-1b-mediated NFkB activation and which cellular signals are involved. On integrin engagement, activated PI3-K has been reported to stimulate ILK activity and induce downstream signalling of Akt and GSK3b (Delcommenne et al., 1998; Attwell et al., 2003; Hannigan et al., 2005; Qian et al., 2005) . Downstream targets of ILK-mediated Akt signalling include NF-kB (Legate et al., 2006) . Our results support the involvement of ILK/integrin signalling in L1CAM-mediated activation of NF-kB, as ILK depletion results in reduced IL-1b expression and NF-kB activity in PT45-P1-L1-FL cells. These data suggest that an interaction of L1CAM with RGDbinding integrins, but not L1CAM cleavage and nuclear translocation, is crucial for IL-1b expression and the induction of NF-kB activity.
In support of this conclusion, we observed that an mAb to the sixth Ig domain of L1CAM (which contains the RGD integrin-binding site) was most potent in the inhibition of NF-kB activity in PT45-P1-L1-FL cells. We also used antibodies to a5-integrins, but the results were rather variable. In addition, an L1-RGE mutant with an impaired integrin-binding ability could not support IL-1b expression and NF-kB activity in PT45-P1 cells. A model to summarize our findings is presented in Figure 8 .
In previous work, we have already shown that the RGD integrin-binding site in human L1CAM is important for nuclear signalling (Gast et al., 2008b) . It is also involved in the resistant phenotype of PT45-P1-L1-FL cells towards chemotherapeutic drugs (Sebens Muerkoster et al., 2009) . We reported that L1-RGEexpressing human embryonic kidney (HEK293) cells showed reduced cell-cell binding, cell motility, invasiveness and tumour growth in NOD/Scid mice. The RGE mutation also impaired L1CAM-dependent gene regulation (Gast et al., 2008b) and abolished the L1CAM-dependent enhanced proliferation of HEK293 cells (J Wolf unpublished results). In the light of our new findings, we can explain these results by the failure of L1-RGE to induce efficient NF-kB activity (see Figure 8 ). These results are reminiscent of an earlier study showing that binding of endothelial cells to the immobilized sixth Ig domain of L1CAM could induce NF-kB activity that was blocked by anti-integrin mAbs (Reidy et al., 2006) . in this study, we want to propose two distinct mechanisms of L1CAM signalling. We term the first mechanism, based on L1CAM-regulated intramembrane proteolysis and nuclear translocation of the L1-cytoplasmic fragment, as 'forward signalling'. Indeed, we showed previously that PT45-P1-L1-FL cells are capable of regulating L1CAM-dependent genes, such as b3-integrin or CRABPII, by 'forward signalling' (Riedle et al., 2009) . In this study, we describe a second pathway of L1CAM-mediated signalling by NF-kB activation that is cleavage independent, addresses different genes and relies on the function of L1-FL as a membranebound ligand to integrins. We specify this mechanism as 'reverse signalling'. Recent evidence showed a crucial role of this signalling by L1CAM and integrins in tumour progression. Blockade of L1CAM binding to integrins abrogates L1CAM-induced tumour growth and reduces L1CAM-mediated chemoresistance (Sebens Muerkoster et al., 2007; Gast et al., 2008a) . Both modes of L1CAM signalling may be functionally active in tumour cells that often express both L1CAM and integrins. The mode of L1CAM signalling that is used by tumour cells under various conditions remains to be studied in more detail. The data presented in this study are an important hallmark in understanding the different L1CAM signalling mechanisms and their impact on the malignancy of PDACs and possibly of other cancers.
Materials and methods
Cells and DNAs
Human PDAC cells Panc-1 or PT45-P1 (Sebens Muerkoster et al., 2007) retrovirally transduced with an empty vector (mock), L1-FL or a fragment encoding the cytoplasmic part of L1CAM (L1cyt) from position 1148G to the C-terminus were described (Riedle et al., 2009) . A fragment encoding the L1CAM ectodomain (L1ecto) from the N-terminus to 1108G was constructed by PCR and inserted into the retroviral vector pBM-Ires-Puro. The site-directed mutagenesis of L1CAM in position D566E (RGD to RGE) was described previously (Gast et al., 2008b) . All constructs were verified by sequencing. The transduction of cell lines with retroviral vectors and selection with puromycin were described (Stoeck et al., 2006b ). All cell lines were cultivated in RPMI1640 supplemented with 10% FCS at 37 1C, 5% CO 2 and 100% humidity.
Chemicals and antibodies
Antibodies to the ectodomain (monoclonal antibody (mAb) L1-11A, a subclone of UJ127.11, mAb L1-9.3, L1-35.9) or cytoplasmic domain (polyclonal Ab pcytL1, mAb 745H7) of human L1CAM were described (Mechtersheimer et al., 2001; Gast et al., 2008a) . The antibodies to phospho-p65 or p65 were from Santa Cruz Biotechnologies (Heidelberg, Germany). Anti IL-1b and IL-RI antibodies were acquired from R&D Systems (Wiesbaden, Germany). PMA, metalloprotease inhibitors (BB-3364 and TAPI-0) and the presenilin inhibitor DAPT were described previously (Riedle et al., 2009) . All other compounds were from Calbiochem (Darmstadt, Germany) or purchased from Sigma-Aldrich (Munich, Germany).
Analysis of L1CAM shedding
For analysis of L1CAM ectodomain shedding, 1 Â 10 5 cells were seeded into six-well plates. Where indicated, cells were treated with PMA, metalloprotease inhibitor or the presenilin inhibitor DAPT. The release of the L1CAM ectodomain into the supernatant was measured by ELISA (Mechtersheimer et al., 2001) .
Biochemical analysis
Cells were seeded into six-well plates and treated as indicated. For cell lysis, 100 ml of 2 Â NuPage LDS sample buffer (Invitrogen, Karlsruhe, Germany) was added per well and the lysates were sonicated. Protein concentrations were determined using the BCA protein assay (Thermo Fisher Scientific, Schwerte, Germany). Sodium dodecyl sulphate-poly acrylamide gel electrophoresis and transfer of separated proteins to Immobilon membranes using semi-dry blotting have been described before (Gutwein et al., 2003) .
Flow cytometry
Staining of cells with mAbs and with PE-conjugated secondary antibodies has been described (Mechtersheimer et al., 2001; Issa et al., 2009) . 
DNA chip analysis
The expression analysis of PT45-P1 mock and L1CAM-domain-transduced cells using the human Sentrix-6 v3 The depletion of a5-integrin or L1CAM abrogates signalling in a manner similar to the mutation of the L1CAM integrin binding site from RGD to RGE.
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BeadChip was performed by the expression profiling core facility (Dr Bernhard Korn) of the German Cancer Research Center, Heidelberg. The detailed procedure has been described before (Wolterink et al., 2010) . Two independent biological replicates were analysed. Genes with fold change of p -1.5 or X 1.5 were regarded as regulated and the gene expression of selected candidates was verified using qRT-PCR.
Quantitative real-time PCR qRT-PCR was performed as described before (Riedle et al., 2009) . Primers for qRT-PCR were designed using the IDT primer quest programme and were produced by MWG (Ebersberg, Germany). b-Actin was used as an internal standard. The sequences of primers used are available on request.
Luciferase assay Cells (1 Â 10 5 ) were seeded into six-well plates and grown for 24 h and then subjected to jetPEI transfection (Polyplus, Illkirch, France) using 1 mg pGL3-(kB)3-Luc (firefly luciferase; T. Hofmann, DKFZ, Heidelberg, Germany) or pGL3-SV40-Luc (firefly luciferase) with 0.02 mg pRLTK (Renilla luciferase; Promega, Mannheim, Germany). The assay was carried out as described by the manufacturer (Promega).
ELISA assay
Cells (1 Â 10 6 ) were seeded into 10 cm plates and were grown for 24 h. Phospho-NF-kB levels were quantified using PathScan Phospho-NF-kB p65 ELISA (Cell Signalling, Frankfurt, Germany). The assay was performed according to the manufacturer's instructions. Levels of secreted human IL-1b were quantified using the Quantikine-HS human IL-1b immunoassay (R&D Systems, Wiesbaden, Germany). ELISA was performed according to the manufacturer 0 s instructions. Measured IL-1b concentrations were normalized to cell numbers.
Cell adhesion assay
The cell adhesion assay has been described before (Mechtersheimer et al., 2001) .
MTT proliferation assay This assay was described before (Novak-Hofer et al., 2008) .
In vivo experiments Six-week-old NOD/Scid female mice were injected subcutaneously with 5 Â 10 6 PT45-P1 cells. At different time points, the tumour size was measured and volume was calculated using the formula Volume ¼ (Length Â Width 2 )p/6. Tumour growth was monitored for the indicated time period; the mice were then killed and tumours were collected for RNA extraction and lysis. All experiments were carried out under the German animal protection law and were approved by local authorities.
Statistical analysis
For the analysis of statistical significance, Student's t-test was used. P-values in the figures are indicated as follows: *o0.05, **o0.01 ***o0.001.
Abbreviations
ADAM, A Disintegrin And Metalloprotease; IL-1b, Interleukin 1 beta; L1CAM, L1 cell adhesion molecule; L1-FL, L1CAM full length; L1ecto, the ectodomain of L1CAM; L1cyt, the cytoplasmic fragment of L1CAM; L1-RGE, human L1CAM with mutations of RGD to RGE; NF-kB, nuclear factor kappa B; PDAC, pancreatic ductal adenocarcinoma.
